文献速递胃肠外科肝胆胰外科围术期管理与 ERAS

普通外科围术期氨甲环酸应用的系统综述与荟萃分析

Perioperative Use of Tranexamic Acid in General Surgery: A Systematic Review and Meta-Analysis.
PubMed 文献 · JAMA Surg · 2026-01-01

结果显示TXA与术中失血量减少、输血需求降低及大出血事件减少相关,未观察到静脉血栓栓塞或死亡率风险增加。但腹部手术亚组中失血量与输血获益不再显著,肝胆亚组大出血显著减少。

要点

  • 预防性TXA可减少普通外科术中失血、输血需求及大出血事件。
  • TXA未增加静脉血栓栓塞或死亡风险。
  • 腹部手术亚组中失血量与输血获益不显著,需个体化决策。

核心结论

  • 预防性TXA与普通外科术中失血量减少、输血需求降低及大出血事件减少相关,且未观察到血栓栓塞或死亡风险增加。
  • TXA的使用决策应结合患者个体特征和具体手术类型进行个体化考虑。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed、Embase和Cochrane Library自建库至2025年4月3日。
  • 采用随机效应模型合并均数差(MD)和风险比(RR)及95%CI,使用I2统计量评估异质性。

主要发现

  • TXA组术中失血量较低(MD,-35.85 mL;95%CI,-57.20至-14.51 mL;I2=91%;P=.001)。
  • TXA组输血需求减少(RR,0.75;95%CI,0.60-0.94;I2=54%;P=.01)。
  • TXA组大出血事件减少(RR,0.72;95%CI,0.59-0.89;I2=0%;P=.002)。
  • 静脉血栓栓塞(RR,1.09;95%CI,0.62-1.92;I2=15%;P=.75)、死亡率(RR,1.08;95%CI,0.72-1.61;I2=0%;P=.71)及住院时长(MD,-0.54天;95%CI,-1.15至0.06天;I2=73%;P=.08)无显著差异。
  • 腹部手术亚组中,术中失血量和输血需求的获益不再显著;肝胆亚组中TXA与大出血显著减少相关(RR,0.59;95%CI,0.39-0.90;I2=0%;P=.01)。

关键数值与推荐

  • 纳入标准:比较TXA与安慰剂的随机对照试验,成人普通外科手术患者,报告至少1项预设结局。

临床怎么用

  • 普通外科手术中可考虑预防性使用TXA以减少失血、输血及大出血,但需评估血栓栓塞风险。
  • 腹部手术患者使用TXA的获益不明确,应个体化决策。
  • 肝胆手术患者使用TXA可能显著减少大出血事件。

局限性

  • 术中失血量分析存在高度异质性(I2=91%)。
  • 腹部手术亚组中失血量和输血获益不再显著,提示效果受手术类型影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Tranexamic acid (TXA) is increasingly used to minimize perioperative bleeding. However, its efficacy and safety profile across general surgical procedures remains unclear. OBJECTIVE: To evaluate the efficacy and safety of prophylactic TXA in reducing intraoperative blood loss, need for transfusion, and major bleeding in general surgery, while assessing its association with thromboembolic events and mortality. DATA SOURCES: PubMed, Embase, and Cochrane Library were systematically searched from inception to April 3, 2025. STUDY SELECTION: Randomized clinical trials (RCTs) comparing TXA to placebo in adult patients undergoing general surgery and reporting at least 1 predefined outcome of interest were included. DATA EXTRACTION AND SYNTHESIS: Two reviewers independently extracted data and assessed risk of bias. Mean differences (MDs) and risk ratios (RRs) with 95% CIs were pooled using random-effects models. Heterogeneity was assessed using the I2 statistic. RESULTS: Twenty-six RCTs with a total of 6976 patients were included. TXA use was associated with lower intraoperative blood loss (MD, -35.85 mL; 95% CI, -57.20 to -14.51 mL; I2 = 91%; P = .001), reduced need for transfusion (RR, 0.75; 95% CI, 0.60-0.94; I2 = 54%; P = .01), and fewer major bleeding events (RR, 0.72; 95% CI, 0.59-0.89; I2 = 0%; P = .002). No significant differences were found in venous thromboembolism (RR, 1.09; 95% CI, 0.62-1.92; I2 = 15%; P = .75), mortality (RR, 1.08; 95% CI, 0.72-1.61; I2 = 0%; P = .71), and length of stay (MD, -0.54 days; 95% CI, -1.15 to 0.06 days; I2 = 73%; P = .08). In the subgroup analysis restricted to abdominal procedures, the benefits observed in the overall population on intraoperative blood loss and need for transfusion were no longer present. In the hepatobiliary subgroup, TXA was associated with a significant reduction in major bleeding (RR, 0.59; 95% CI, 0.39-0.90; I2 = 0%; P = .01), while no significant differences were observed for the other outcomes. CONCLUSIONS AND RELEVANCE: This systematic review and meta-analysis found that prophylactic TXA use was associated with lower intraoperative blood loss, transfusion requirements, and major bleeding without an observed increase in thromboembolic or mortality risk. Although these findings support the use of TXA in general surgery procedures, the decision to use TXA should be individualized considering individual patient characteristics and the specific procedure being performed.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. Delgado LM, Pompeu BF, Martins GHA, et al. Perioperative Use of Tranexamic Acid in General Surgery: A Systematic Review and Meta-Analysis. JAMA Surg. 2026. PMID: 41405985. doi:10.1001/jamasurg.2025.5498

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。